Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN)
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Berenberg Bank Keeps Their Hold Rating on Novartis AG (NOVN)
Novartis AG (NOVN) Gets a Buy From Kepler Capital
Novartis AG (NOVN) Gets a Buy From Deutsche Bank
DA Davidson Downgrades Novartis to Neutral From Buy, Price Target Is $120
J.P. Morgan Sticks to Their Hold Rating for Novartis AG (NOVN)
Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis Analyst Ratings
Novartis AG (NOVN) Gets a Buy From Deutsche Bank
Novartis Target Cut to CHF104 From CHF111 by UBS
Novartis Cut to Neutral From Buy by UBS
UBS Downgrades Novartis AG (NOVN) to a Hold
Goldman Sachs Keeps Their Hold Rating on Novartis AG (NOVN)
Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
Goldman Sachs Sticks to Their Hold Rating for Novartis AG (NOVN)
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), HOYA (OtherHOCPF) and Novartis AG (Six Swiss: CH:NOVN)
Novartis Raised to Buy by Deutsche Bank
Novartis Target Raised to CHF110.00 From CHF100.00 by Deutsche Bank